Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that its CEO, Greg Divis, will participate in a fireside chat on July 14 at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that its CEO, Greg Divis, will participate in a fireside chat on July 14 at 11:00 a.m. ET. The discussion will focus on FT218, an investigational treatment for excessive daytime sleepiness and cataplexy in adults with narcolepsy. A live webcast will be available on Avadel’s Investor Relations website, along with an archived recording accessible for 90 days after the event. This engagement highlights Avadel's commitment to advancing its innovative therapies.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was -1.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Wednesday, July 14 at 11:00 a.m. ET.
A live webcast of this event, as well as an archived recording, will be available on Avadel’s Investor Relations website, www.investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.